Over the next couple of weeks, there are several companies to keep an eye on that I haven't necessarily talked about or mentioned in a news recap. It appears most have good things in the works and I have future articles tentatively planned for them
Cleveland BioLabs Inc. (CBLI) - They recently announced that CBLB502, a drug under development for the treatment of Acute Radiation Syndrome (ARS), has been granted Fast Track status by the U.S. Food and Drug Administration (FDA). You should check out their recent 10K.
Cyclacel Pharmaceuticals, Inc. (CYCC) - At these levels, I think CYCC is a good buy. I think 3-6 months from now, they should be back at the $2-3 levels. Everyone is still waiting to hear news about an SPA for sapacitabine in AML and MDS. I think the more recent news regarding orphan drug status for sapacitabine (CYC682) product candidate for the treatment of both acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). This could be hint of things to come, but who knows. I will watch closely for it to retest the low 1.50's.
Depomed Inc (DEPO) - They are a very strong biotech that has good revenues and a lot of cash on hand. If their recent NDA submission for DM-1796 clears any potential legal hurdles, this thing should take off. A lot of investors seems worried that a potential lawsuit from Pfizer Inc.(PFE) could derail it. The 45-day waiting period should be up soon for PFE to take action. I also imagine Glumetza sales will be a little low because of the recall of the 500mg, but they still have money coming in. They scored $10 million for submitting DM-1796 to the FDA.
0 comments:
Post a Comment